Drug Database
TA

tamsulosin

✓ Approved

Ethypharm Corp. · ADRA1A · Small Molecule

What is tamsulosin?

tamsulosin is a small molecule developed by Ethypharm Corp.. It is approved for therapeutic indications via oral (po).

Drug Profile

CompanyEthypharm Corp.
Drug ClassSmall Molecule
Molecular TargetADRA1A
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Ethypharm Corp.

Mechanism of Action

Molecular Targets

tamsulosin acts on 1 molecular target:

ADRA1Aadrenoceptor alpha 1A (ALPHA1AAR, ADRA1C)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

tamsulosin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Reproductive system and breast disordersBenign prostatic hyperplasia✓ Approved

Related Research Articles

PubMedIndian journal of orthopaedics2026-10-14

Efficacy and Safety of Tamsulosin in the Prevention of Postoperative Urinary Retention in Hip Fractures (TamPOUR-Hip Trial): A Randomized, Double-Blind Placebo-Controlled Study.

Tripathy Sujit Kumar SK, Varghese Paulson P, Khan Shahnawaz S, Patel Ranjan Kumar RK et al.

Postoperative urinary retention (POUR) is a common problem after hip fracture surgery in the elderly patients, leading to increased morbidity, catheterization, and prolonged hospitalization. Tamsulosin, an α1-adrenergic antagonist, may reduce POUR by decreasing bladder outlet resistance. This study evaluated the efficacy and safety of perioperative tamsulosin in preventing POUR in hip fracture patients. In this prospective, randomized, double-blind, placebo-controlled trial, 120 patients undergoing hip fracture surgery under spinal anaesthesia were allocated to receive either tamsulosin (0.4 mg daily) or placebo from admission until the second postoperative day. Foley catheter was removed on postoperative day one, and POUR was defined as post-void residual urine > 200 mL at six hours of catheter removal. Primary outcome was incidence of POUR; secondary outcomes included indwelling re-catheterization rates, urinary tract infections (UTIs), and adverse events. POUR was observed in 16.7% of patients in the tamsulosin group compared with 33.3% in the placebo group. Tamsulosin significantly reduced the pre-void bladder volume (311.3 ± 174.5 mL vs. 402.9 ± 198.4 mL; p = 0.008) and post-void residual urine volume (median 20 mL vs. 53.5 mL; p < 0.001). Re-catheterization was less frequent with tamsulosin (8.3% vs. 21.7%), though not statistically significant. Multivariate logistic regression analysis identified female sex, longer surgical duration, and blood loss as independent risk factors for POUR, while tamsulosin use was not found to be preventive. Adverse events, including dizziness and postural hypotension, were mild and self-limiting. Perioperative tamsulosin was safe and improved bladder emptying, but did not significantly reduce the incidence of POUR in elderly patients undergoing hip fracture surgery. Larger multicentric studies are needed to further clarify its role in this population.

PMID 42871280
Read full article →
PubMedJournal of pediatric urology2026-09-30

Efficacy and safety of medical expulsive therapy (MET) after extracorporeal shockwaves lithotripsy (SWL) in pediatric patients.

Hassan Ahmed Bakr Eldesouky ABE, Sheir Khaled Zaki KZ, Elshal Ahmed Mohamed AM, Bazeed Mahmoud Anees MA et al.

To evaluate the impact of tamsulosin as a post-SWL adjunctive treatment for pediatric urolithiasis. A randomized controlled trial (RCT) was carried out for children with renal stones amenable for SWL. Eligible children were randomized into 2 groups. Group 1 received tamsulosin (0.01 mg/kg once daily) for 2 weeks after each SWL session while group 2 served as a control. Stone clearance was defined as no residual fragments by low-dose non-contrast computed tomography (NCCT) at one and three months after last session. A total of 106 patients were included (53 in each group). Pre-SWL patients and stone criteria were comparable between both groups. Stone clearance was achieved in 43 patients (81.1%) in group 1 and 36 patients (67.9%) in group 2 (P = 0.119). Time to stone clearance was comparable for both groups (P = 0.110). Post-SWL complications were encountered in one patient (1.9%) in group 1 and three patients (5.7%) in group 2 (P = 0.308). Tamsulosin minor adverse effects were observed in 18.9%, but no patients discontinue treatment. Tamsulosin treatment following SWL for renal stones in children showed trends for increasing SFR and decreasing complications in comparison with control group. However, statistically significant differences were not achieved.

PMID 42816303
Read full article →
PubMedCureus2026-09-27

Prescription Trends in the Management of Lower Urinary Tract Symptoms in Men: An Online Survey of Indian Urologists.

Patwardhan Prakash P, Palkar Santosh S, Sharma Rahul R, Kamble Sanjay S et al.

Background Lower urinary tract symptoms (LUTS), highly prevalent among aging men, adversely affect the quality of life. Pharmacological management has evolved with multiple drug classes, but real-world prescribing patterns in India have not been adequately studied. Thus, we evaluated prescription trends among Indian urologists for the management of male LUTS, assessed symptom patterns, evaluated factors influencing choice of fixed-dose combination (FDC), with special focus on silodosin-mirabegron FDC, and identified adverse events (AEs) and adherence. Methods This cross-sectional, questionnaire-based survey was performed over three months (January 2, 2026, to April 5, 2026) and included 110 Indian urologists actively managing male patients with LUTS. A 27-item structured questionnaire captured demographic characteristics, clinical practice patterns, and prescribing preferences for LUTS pharmacotherapy, including monotherapies, combination therapies, and FDCs, along with AEs and adherence. Results Of 135 urologists invited, 110 (81.48%) completed the survey. LUTS mainly involved a combination of storage, voiding, and post-micturition symptoms (n = 59, 53.6%). As a class, α1-blockers were the most frequently prescribed monotherapy (n = 109, 99.1% frequent/very frequent use), with silodosin (n = 98, 89.1%) and tamsulosin (n = 84, 76.4%) being most preferred. Use of dutasteride (n = 108, 98.2%) exceeded finasteride (n = 13, 11.8%). In patients with benign prostatic hyperplasia (BPH) with overactive bladder, silodosin-mirabegron was the most favored FDC (n = 97, 88.2%). FDCs of α1-blockers with muscarinic receptor antagonists and β-3 adrenergic agonists were preferred due to their proven efficacies (n = 83, 75.5% and n = 87, 79.1%, respectively) and lower incidences of AEs (n = 69, 62.7% and n = 80, 72.7%). Common AEs included dry mouth (n = 73, 66.4%), anejaculation (n = 69, 62.7%), and headache (n = 67, 60.9%). Moderate adherence (25%-75%) was reported by 95 (86.4%) urologists. Conclusion Adherence to pharmacotherapy, as assessed by participating urologists, was moderate, with urologists preferring silodosin as first-line therapy and silodosin-mirabegron FDC for mixed LUTS.

PMID 42799232
Read full article →
PubMedJournal of clinical medicine2026-09-26

Effect of Tamsulosin on Nocturnal Blood Pressure Load and Dipping Status: A Prospective Ambulatory Blood Pressure Monitoring Study.

Yesildal Cumhur C, Yilmaz Anil A, Hayit Huseyin H, Keskin Nurgul N et al.

Background: Alpha-1 adrenergic receptor antagonists are widely used in the management of benign prostatic hyperplasia (BPH) . Their effects on blood pressure (BP) patterns remain incompletely characterized. This study aimed to prospectively evaluate the impact of tamsulosin on ambulatory blood pressure monitoring (ABPM) parameters, with particular focus on nocturnal BP load and dipping status. Methods: A total of 83 male patients aged 40-90 years who were initiated on tamsulosin for BPH-related lower urinary tract symptoms (LUTS) were prospectively enrolled; 58 patients with complete, technically adequate paired recordings were included in the final analysis. Participants underwent 24 h ABPM before treatment and at 1 month. Dipping status was defined as a nocturnal BP reduction ≥10%. Pre-post treatment ABPM parameters were compared using paired statistical analyses, and changes in dipping status were evaluated using McNemar's test. Results: Mean 24 h, daytime, and nighttime systolic and diastolic blood pressure (DBP) values did not change significantly after treatment (p > 0.05). However, nocturnal systolic and DBP load decreased significantly following tamsulosin initiation (p = 0.035 and p = 0.005, respectively), along with a reduction in minimum DBP (p < 0.001). Changes in dipping status were heterogeneous: 25% of baseline non-dippers converted to a dipper pattern, whereas 36.4% of initial dippers became non-dippers, with no statistically significant overall shift (p = 0.81). Conclusions: At one month, tamsulosin was not associated with significant changes in mean ambulatory BP. Reductions in nocturnal BP load were observed, but the incremental clinical significance of BP load beyond mean ambulatory BP indices is uncertain. The marked decrease in minimum DBP warrants cautious interpretation as a potential safety signal. These findings should be considered exploratory and require confirmation in controlled studies incorporating earlier and longer follow-up.

PMID 42795885
Read full article →
PubMedInternational urology and nephrology2026-09-24

Temporary pharmacologically induced ejaculatory dysfunction influences surgical decision-making in sexually active men with benign prostatic hyperplasia: a prospective interventional study.

Iossa Vincenzo V, Imperatore Vittorio V, Buonopane Roberto R, Di Girolamo Antonio A et al.

The aim of this study was to evaluate whether temporary pharmacologically induced ejaculatory dysfunction influences treatment preference among sexually active men undergoing preoperative counseling for surgical management of benign prostatic hyperplasia (BPH). A prospective, single-center, exploratory interventional study was conducted including 71 sexually active men with moderate-to-severe lower urinary tract symptoms secondary to BPH who were eligible for both transurethral resection of the prostate (TURP) and water vapor thermal therapy (Rezūm). Following standardized counseling, the patients recorded their preferred treatment before and after a 4-week course of tamsulosin 0.4 mg daily. The primary analysis included patients who developed clinically relevant tamsulosin-induced ejaculatory dysfunction. Urinary symptoms, erectile function, ejaculatory function, ejaculatory bother, and the perceived importance of ejaculation were assessed using validated questionnaires. Clinically relevant tamsulosin-induced ejaculatory dysfunction occurred in 35 of 71 patients (49.3%), who constituted the prespecified evaluable cohort. Among these patients, 12 (34.3%) changed their initial treatment preference following tamsulosin exposure. Nine patients switched from TURP to Rezūm, while three patients initially choosing TURP opted for conservative management. No patient changed preference from Rezūm to TURP. Overall, a significant shift away from TURP was observed after experiencing ejaculatory dysfunction (P < 0.001). Urinary symptoms and erectile function remained unchanged, whereas ejaculatory function significantly worsened, ejaculatory bother increased, and patients attributed greater importance to preserving ejaculation (P < 0.001 for all). Temporary pharmacologically induced ejaculatory dysfunction was associated with a significant change in treatment preference in a substantial proportion of sexually active men undergoing counseling for BPH surgery. These findings suggest that experiential exposure to reversible ejaculatory dysfunction may represent a novel, hypothesis-generating decision-support strategy, complementing conventional counseling. Further studies are needed to validate this approach and to assess its impact on actual treatment selection and long-term satisfaction.

PMID 42782435
Read full article →
PubMedReports (MDPI)2026-09-24

Localized Multidrug-Resistant Morganella morganii Urinary Tract Infection in a Dapagliflozin-Treated Man with Bladder Outlet Obstruction and Incomplete Ureteral Duplication: A Case Report.

Nicolae Camelia C, Munteanu Madalina Andreea MA, Petca Razvan R, Rascu Stefan Alexandru SA et al.

Background and Clinical Significance: Sodium-glucose cotransporter-2 (SGLT2) inhibitors cause persistent glucosuria, which has been hypothesized to facilitate urinary tract infection (UTI) when urinary stasis or anatomic variants coexist; causality, however, remains unproven and almost certainly multifactorial. Case Presentation: A 72-year-old man treated with dapagliflozin 10 mg/day for 4 months presented with 3 days of dysuria and nocturia, without fever or systemic signs. One month before SGLT2 inhibitor initiation, urological work-up had been unremarkable: prostate ~50 cm3, post-void residual (PVR) 0 mL, and a negative midstream culture. At presentation we obtained a midstream clean-catch specimen before antibiotics. Dipstick showed glucose 2+ (~100 mg/dL, as expected with SGLT2 inhibition), leukocyte esterase 3+ and nitrites negative; microscopy revealed 45 leukocytes/high-power field with pronounced bacteriuria. Quantitative culture grew Morganella morganii at 1 × 105 CFU/mL in pure culture. Antimicrobial susceptibility (VITEK® 2 Compact, EUCAST v14.0, 2024) demonstrated resistance to ampicillin, amoxicillin-clavulanate, ampicillin-sulbactam, ceftriaxone, ceftazidime, gentamicin and trimethoprim-sulfamethoxazole, with susceptibility (S) retained only to piperacillin-tazobactam, levofloxacin/norfloxacin, cefepime and carbapenems (ertapenem, meropenem). Imaging revealed a right duplicated ureter with distal fusion (single bladder insertion, no dilatation or obstruction) and benign prostatic hyperplasia with PVR ~100 mL; renal function was preserved, two blood culture sets (pre-antibiotic) were negative, and repeat urine culture on day 7 was sterile. Management/outcome: The episode was classified as a localized (cystitis-range) UTI per European Association of Urology (EAU) criteria (no fever, flank pain or bacteremia). Meropenem 1 g intravenously every 8 h (3 g/day) was given for 10 days after urology/infectious-disease review. Dapagliflozin was held at presentation and not restarted during the 3-month follow-up period; reintroduction was planned only after full urological reassessment with cardiology input. Transurethral resection of the prostate (TUR-P) was performed 18 days after completing antibiotics (28 days after presentation) for bladder outlet obstruction refractory to tamsulosin 0.4 mg daily, with complete resolution of symptoms, normalization of inflammatory markers and PVR 0 mL. No recurrence occurred during 3 months of follow-up after TUR-P. Conclusions: This single case illustrates a temporal association-not proven causation-between SGLT2-related glucosuria, incomplete emptying and a non-obstructive duplicated ureter that likely created a permissive milieu for opportunistic Morganella UTI. The narrative is hypothesis-generating; urinary stasis was the dominant modifiable factor. Culture-guided therapy, individualized decisions on SGLT2 continuation, and definitive correction of outlet obstruction are the practical takeaways.

PMID 42784017
Read full article →

+2313 more articles available with a free account

Sign up free to view all articles →

Ask about tamsulosin